Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.
复制标题
在接受免疫抑制治疗的多发性硬化症患者中，JC多瘤病毒，病毒血症，血统和microRNA表达的诊断值。
DOI：
10.3390/jcm11020347
复制
发表时间：
2022-01-11
影响因子：
3.9
通讯作者：
Pietropaolo V
中科院分区：
文献类型：
--
作者：
Prezioso C;Ciotti M;Brazzini G;Piacentini F;Passerini S;Grimaldi A;Landi D;Nicoletti CG;Zingaropoli MA;Iannetta M;Altieri M;Conte A;Limongi D;Marfia GA;Ciardi MR;Mastroianni CM;Palamara AT;Moens U;Pietropaolo V
JC多瘤病毒（JCPyV）活性标志物可用于评估经治疗的多发性硬化（MS）患者发生进行性多灶性白质脑病（PML）的风险。在42名MS受试者中测定了治疗前（T0）、那他珠单抗、ocrelizumab、芬戈莫德或富马酸二甲酯给药后6个月（T6）和12个月（T12）以及25名健康对照（HC）中JCPyV DNA和microRNA（miR-J1- 5 p）的存在、抗JCV指数和尿液和血浆中非编码对照区（NCCR）的序列。MS病毒尿患者的数量从T0时的43%增加至T12时的100%，而HC组保持相似（35-40%）。病毒血症首先发生在MS患者治疗后6个月，并在12个月后增加，而在HC中不存在。MS队列的尿液和血浆中的病毒载量随时间推移而增加，在那他珠单抗治疗的患者中最明显，而在HC中持续存在。在所有阳性尿液中均检测到原型NCCR，而在血浆来源的NCCR中观察到突变，导致更具嗜神经性的变体。治疗后MS尿液和血浆中的患病率和miR-J1- 5 p拷贝数下降，而HC标本中的患病率和miR-J1- 5 p拷贝数保持相似。病毒尿和miR-J1- 5 p表达与抗JCV指数无关。总之，分析JCPyV DNA和miR-J1- 5 p水平可以监测JCPyV活性并预测MS患者发生PML的风险。
Markers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0), 6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate administration and in 25 healthy controls (HC). The number of MS patients with viruria increased from 43% at T0 to 100% at T12, whereas it remained similar for the HC group (35–40%). Viremia first occurred 6 months after treatment in MS patients and increased after 12 months, whereas it was absent in HC. The viral load in urine and plasma from the MS cohort increased over time, mostly pronounced in natalizumab-treated patients, whereas it persisted in HC. The archetypal NCCR was detected in all positive urine, whereas mutations were observed in plasma-derived NCCRs resulting in a more neurotropic variant. The prevalence and miR-J1-5p copy number in MS urine and plasma dropped after treatment, whereas they remained similar in HC specimens. Viruria and miR-J1-5p expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.
登录
查看更多内容
影响因子：
4.8
作者：
Lagatie O;Van Loy T;Tritsmans L;Stuyver LJ
通讯作者：
Stuyver LJ
影响因子：
64.8
作者：
Lu, J;Getz, G;Golub, TR
通讯作者：
Golub, TR
循环的人类microRNA与健康受试者中的JC多瘤病毒血清学或尿病毒负荷无关。
影响因子：
4.8
作者：
Lagatie O;Van Loy T;Tritsmans L;Stuyver LJ
通讯作者：
Stuyver LJ
影响因子：
6.7
作者：
Kincaid RP;Sullivan CS
通讯作者：
Sullivan CS
影响因子：
4.5
作者：
Mamana AC;Stincarelli M;Sarmento DJS;Mendes Batista A;Tozetto-Mendoza TR;Gallottini M;De Abreu Pestana JOM;Braz-Silva PH;Giannecchini S
通讯作者：
Giannecchini S